Piramal Pharma to acquire remaining 26% stake in Yapan Bio
Piramal Pharma announced that it will acquire the remaining 26 percent stake in Yapan Bio, giving it full ownership of the company. The deal will integrate Yapan Bio’s large molecule expertise into Piramal’s service platform.

Piramal Pharma, a major player in the Indian contract development and manufacturing sector, has moved to complete its purchase of Yapan Bio, a biotech firm known for its work on complex protein‑based medicines. The transaction, valued at several hundred million rupees, will give Piramal 100 percent control over Yapan Bio’s assets, research facilities and client contracts. This step follows an earlier agreement in which Piramal bought a 74 percent share, leaving the remaining portion under the control of Yapan’s founders.
Yapan Bio’s capabilities in large molecule development include cell culture, purification and analytical services that are essential for the production of biologics such as monoclonal antibodies and therapeutic enzymes. By bringing these services under one roof, Piramal aims to offer end‑to‑end solutions to pharmaceutical companies that are increasingly looking for partners who can handle both small and large molecule projects. Industry analysts note that the move could help Piramal attract new business from global firms seeking to outsource complex biologics work.
For Indian biotech and pharmaceutical firms, the acquisition signals a growing confidence in the country’s ability to support advanced drug development. It may also encourage further investment in research infrastructure and talent development, as companies look to expand their service portfolios. Observers expect that the combined entity will focus on expanding its client base in North America and Europe while strengthening its presence in the domestic market.
Comments 0